Morgan Stanley’s Anbio Biotechnology NNNN Stock Holding History

Morgan Stanley’s Portfolio NNNN Stock Details NNNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$99.1K	Sell	7,231 -107	-1%	-$2.68K	﹤0.01%	6259
2026 Q1	$189K	Buy	7,338 +7,310	+26,107%	+$191K	﹤0.01%	5902
2025 Q4	$842	Sell	28 -8,582	-100%	-$236K	﹤0.01%	7407
2025 Q3	$321K	Buy	8,610 +8,210	+2,053%	+$369K	﹤0.01%	5699
2025 Q2	$12.7K	Buy	+400	New	+$3.83K	﹤0.01%	6785

Other funds holding NNNN

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFS

Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return

LFG

Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

Morgan Stanley's NNNN Position: Q2 2026 in Review

Morgan Stanley reduced its Anbio Biotechnology (NNNN) stake by 1.5% in Q2 2026, selling an estimated $2.68K and leaving 7,231 shares worth $99.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6259.

Morgan Stanley first reported a position in NNNN in Q2 2025 and has held it in 5 quarters since. The position peaked at $321K in Q3 2025. 12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

Morgan Stanley held 7,231 shares of Anbio Biotechnology worth $99.1K as of Q2 2026.
Morgan Stanley sold 107 Anbio Biotechnology shares in Q2 2026, an estimated $2.68K.
Anbio Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6259 holding.
Morgan Stanley first reported a position in Anbio Biotechnology in Q2 2025 and has held it in 5 quarters since.
Morgan Stanley's Anbio Biotechnology position peaked at $321K in Q3 2025.
12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.